Vor Biopharma (VOR) Stock Forecast & Price Target

Vor Biopharma is viewed favorably because telitacicept continues to show strong clinical validation, including the May 14, 2026 NEJM publication of the TELIGAN Phase 3 interim analysis, which reported a 55.0% placebo-adjusted reduction in 24-hour UPCR at week 39, flatter eGFR, and fewer serious adverse events versus placebo. Its franchise potential is reinforced by approvals in China across SLE, RA, and gMG, ongoing global Phase 3 programs in gMG and Sjögren’s disease, and an estimated US addressable population that could expand from about 380K to more than 1M patients. Financially, the company ended the quarter with $491.5MM in cash, cash equivalents, and marketable securities, which it expects will fund operations into early 2029.

Vor Biopharma is fundamentally exposed to a single lead asset, telitacicept, so any clinical or regulatory setback in target indications would materially impair the investment case and could halt development entirely. The company also faces meaningful commercialization risk because telitacicept may struggle to achieve sales estimates or compete against current and future therapies, while manufacturing or shipment problems could further delay adoption. Despite net cash and cash equivalents of $491.5M and a rNPV-based valuation of $2.9B, the outlook remains negative because the business is vulnerable to clinical, commercial, collaboration, dilution, and legal or intellectual property risks.